Tag: Tradjenta

Eli Lilly and Boehringer Ingelheim presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin, marketed under the name Tradjenta in the U.S, at the American Diabetes Association's (ADA) 72nd Scientific Sessions. The new studies...

Boehringer Ingelheim and Eli Lilly announced results of a Phase 3 study in African American adults that shows taking Tradjenta (linagliptin) 5mg once-daily tablets sgnificantly reduces hemoglobin A1c (HbA1c)...

The new type 2 diabetes drug Trajenta (linagliptin 5 mg film-coated tablets) received Marketing Authorization from the European Commission for the treatment of type 2 diabetes. The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea. Linagliptin is also approved for use as monotherapy in patients...

The new type 2 diabetes drug Tradjenta (linagliptin) is now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid following the U.S. Food and Drug Administration (FDA) approval of the drug on May 2, 2011. Tradjenta was approved as a prescription medication to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes...

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly's type 2 diabetes drug Tradjenta (linagliptin) as a medication used along with diet and exercise to lower blood sugar in adult patients. The drug can be used as monotherapy or in combination with other commonly prescribed medications...

This week at the 46 th Annual Meeting of the European Association for the Study of Diabetes (EASD) Boehringer Ingelheim presented data from its linagliptin phase III clinical trial. Linagliptin belongs to the novel class of DPP-4 inhibitors and is currently...